Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Roivant Sciences Ltd (ROIVW)
Roivant Sciences Ltd (ROIVW) News

ROIVW

Roivant Sciences (ROIVW)

Roivant Sciences Ltd

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ROIVW

1 2 3 Next >>

Date	Time	Source	Headline	Symbol	Company
05/30/2024	7:00AM	GlobeNewswire Inc.	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
05/16/2024	4:05PM	GlobeNewswire Inc.	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	NASDAQ:ROIVW	Roivant Sciences Ltd
04/02/2024	7:00AM	GlobeNewswire Inc.	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	NASDAQ:ROIVW	Roivant Sciences Ltd
02/13/2024	7:00AM	GlobeNewswire Inc.	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
01/30/2024	4:05PM	GlobeNewswire Inc.	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024	NASDAQ:ROIVW	Roivant Sciences Ltd
12/20/2023	4:30PM	GlobeNewswire Inc.	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease	NASDAQ:ROIVW	Roivant Sciences Ltd
12/14/2023	9:00AM	GlobeNewswire Inc.	Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease	NASDAQ:ROIVW	Roivant Sciences Ltd
11/28/2023	7:00AM	GlobeNewswire Inc.	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential	NASDAQ:ROIVW	Roivant Sciences Ltd
11/27/2023	8:00AM	GlobeNewswire Inc.	Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus	NASDAQ:ROIVW	Roivant Sciences Ltd
11/13/2023	7:00AM	GlobeNewswire Inc.	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
11/10/2023	8:00AM	GlobeNewswire Inc.	Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors	NASDAQ:ROIVW	Roivant Sciences Ltd
10/30/2023	5:30PM	GlobeNewswire Inc.	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023	NASDAQ:ROIVW	Roivant Sciences Ltd
10/23/2023	1:00AM	GlobeNewswire Inc.	Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant	NASDAQ:ROIVW	Roivant Sciences Ltd
09/26/2023	6:00AM	GlobeNewswire Inc.	Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results	NASDAQ:ROIVW	Roivant Sciences Ltd
09/11/2023	8:00AM	GlobeNewswire Inc.	Roivant Announces Completion of Redemption of its Outstanding Warrants	NASDAQ:ROIVW	Roivant Sciences Ltd
08/17/2023	4:05PM	GlobeNewswire Inc.	Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants	NASDAQ:ROIVW	Roivant Sciences Ltd
08/14/2023	7:00AM	GlobeNewswire Inc.	Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
08/03/2023	4:05PM	GlobeNewswire Inc.	Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023	NASDAQ:ROIVW	Roivant Sciences Ltd
08/02/2023	4:05PM	GlobeNewswire Inc.	Roivant Announces Redemption of Outstanding Warrants	NASDAQ:ROIVW	Roivant Sciences Ltd
07/27/2023	8:00AM	GlobeNewswire Inc.	Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease	NASDAQ:ROIVW	Roivant Sciences Ltd
07/13/2023	11:06PM	KR Market News	로이반트, 로슈에 $70억 가치의 장 치료제 판매 협상 중	NASDAQ:ROIVW	Roivant Sciences Ltd
07/11/2023	8:00AM	GlobeNewswire Inc.	Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program	NASDAQ:ROIVW	Roivant Sciences Ltd
06/28/2023	8:57AM	GlobeNewswire Inc.	UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
06/28/2023	7:00AM	GlobeNewswire Inc.	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update	NASDAQ:ROIVW	Roivant Sciences Ltd
06/26/2023	4:05PM	GlobeNewswire Inc.	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023	NASDAQ:ROIVW	Roivant Sciences Ltd
06/22/2023	7:30AM	GlobeNewswire Inc.	Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period	NASDAQ:ROIVW	Roivant Sciences Ltd
06/21/2023	5:00PM	GlobeNewswire Inc.	Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis	NASDAQ:ROIVW	Roivant Sciences Ltd
05/16/2023	7:00AM	GlobeNewswire Inc.	Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old	NASDAQ:ROIVW	Roivant Sciences Ltd
03/28/2023	8:00AM	GlobeNewswire Inc.	Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients	NASDAQ:ROIVW	Roivant Sciences Ltd
03/15/2023	7:45AM	GlobeNewswire Inc.	Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old	NASDAQ:ROIVW	Roivant Sciences Ltd

Showing the most relevant articles for your search:NASDAQ:ROIVW

1 2 3 Next >>

International Endeavors (PK)

AMC Entertainment

Asia Broadband (PK)

North Bay Resources (PK)

NaturalShrimp (QB)

Cann American (CE)

Ecare Solutions (PK)

Kraig Biocraft Laborator... (QB)

Voip Pal Com (QB)

Lightwave Logic

Fannie Mae (QB)

Code Green Apparel (PK)

Elite Pharmaceuticals (QB)

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions